R&D News

Partnering Opportunity Now Open for DD01, a Dual GLP-1/GCG Agonist Targeting MASH

A partnering opportunity is now open for DD01, a promising investigational therapy developed by D&D Pharmatech for the treatment of metabolic dysfunction-associated steatohepatitis (MASH). As of April 2nd, the company has announced the successful grant of a key patent in Australia, further strengthening the global intellectual property position of this candidate. DD01 is a long-acting dual GLP-1/glucagon receptor agonist with demonstrated potential in reducing liver fat and addressing the roo...

D&D Pharmatech2025-04-02

Partnering Opportunity for ABN401 (Vabametkib): A Potent Oral MET Inhibitor Targeting Global Markets

Abion, a clinical-stage oncology company specializing in precision cancer therapies, is actively seeking global partners to co-develop and commercialize ABN401 (Vabametkib) — a potent, selective, oral c-MET inhibitor currently in Phase 2 clinical development for non-small cell lung cancer (NSCLC). Earlier this year, Abion signed a term sheet with a global pharmaceutical company headquartered in Russia, initiating a licensing deal for the Russia and CIS (Commonwealth of Independent States) mar...

Abion2025-04-01

D&D Pharmatech Highlights GLP-1 Agonists’ Potential for Parkinson’s Treatment Amid Growing Research Evidence

D&D Pharmatech announced on the 14th that its investigational Parkinson’s disease treatment, NLY01, has been prominently featured in recent studies on GLP-1 receptor agonists and their potential neuroprotective effects in degenerative brain diseases. GLP-1 receptor agonists are believed to inhibit microglial activation, a key driver of neuroinflammation linked to neurodegenerative disorders, thereby protecting neurons. Reflecting this potential, Novo Nordisk is conducting a global Phase 3 tri...

D&D Pharmatech2025-03-19

Alteogen Signs Exclusive Licensing Deal with AstraZeneca’s MedImmune for ALT-B4 SC Cancer Therapy

Alteogen announced on February 17 that it has signed an exclusive licensing agreement with AstraZeneca’s subsidiary, MedImmune, for the development and commercialization of a subcutaneous (SC) version of its oncology drugs using Alteogen’s human hyaluronidase technology, ALT-B4. Under the agreement, Alteogen will receive an upfront payment of $25 million (approximately 36.37 billion KRW) and milestone payments of up to $725 million (approximately 1.054 trillion KRW) upon successful completion...

Alteogen2025-03-19

Onconic Therapeutics’ Cancer Drug ‘Nesuparib’ Receives FDA Orphan Drug Designation for Gastric and Gastroesophageal Junction Cancer

Onconic Therapeutics2025-03-18

AprilBio’s IL-18 Inhibitor ‘APB-R3’ Begins Phase 2 Trial in the U.S.

APRILBIO2025-03-18

Excell Therapeutics Completes FDA DMF Registration for MSC Culture Medium ‘CellCor MSC CD AOF’

Excell Therapeutics announced on February 25 that it has completed the U.S. Food and Drug Administration (FDA) Drug Master File (DMF) registration for CellCor MSC CD AOF, its chemically defined culture medium for mesenchymal stem cell (MSC) cultivation. The DMF system allows manufacturers to register information on raw material production processes and quality control to ensure the safety and quality of pharmaceutical ingredients. Released in June 2023, CellCor MSC CD AOF is composed entirely...

Xcell Therapeutics2025-02-25

Abclon to Pursue Fast-Track Approval for CAR-T Therapy ‘AT101’ Following Positive Phase 2 Progress

AbClon2025-02-18

BridgeBio Therapeutics Advances Phase 1 Trial of 4th-Generation EGFR Inhibitor ‘BBT-207’

BridgeBio therapeutics announced on February 13 that it has completed the review of patient dosing data from the fifth cohort of its Phase 1 dose-escalation study for BBT-207, a fourth-generation EGFR tyrosine kinase inhibitor (TKI) for non-small cell lung cancer (NSCLC), during its fifth Safety Monitoring Committee (SMC) meeting. In the Phase 1 trial, BBT-207 is undergoing stepwise dose escalation to evaluate its safety and efficacy. After each cohort completes dosing, an SMC comprising key ...

Bridgebio Therapeutics2025-02-18

Genome & Company Licenses Immuno-Oncology Drug ‘GENA-104’ to UK’s Ellipses Pharma

Genome & Company has signed a licensing agreement with UK-based Ellipses Pharma for its immuno-oncology drug GENA-104, the companies announced on February 11 (local time). Financial details of the deal, including upfront payments, were not disclosed. GENA-104, an antibody targeting the CNTN4 protein, was developed by Genome & Company. CNTN4 is a novel immune checkpoint protein highly expressed in various tumors, offering a potential treatment option for patients who do not respond to existing...

Genome & Co.2025-02-17

DAAN Biotherapeutics Licenses Novel Anticancer Antibody to LigaChem Biosciences for ADC Development

DAAN Biotherapeutics announced on February 13 that it has signed an exclusive global licensing agreement with LigaChem Biosciences for the development and commercialization of an antibody-drug conjugate (ADC) targeting a novel cancer antigen. While the specific target remains undisclosed, LigaChem confirmed that the antibody targets an antigen protein expressed in various solid tumors, including lung and colorectal cancers. Currently, no commercialized ADCs target this antigen, though several...

DAAN Biotherapeutics2025-02-17

Rznomics Secures FDA Fast Track Designation for Liver Cancer Gene Therapy ‘RZ-001’

Rznomics announced on February 14 that its RNA-based anticancer candidate, RZ-001, has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for the treatment of hepatocellular carcinoma (HCC). RZ-001 utilizes the company’s proprietary RNA trans-splicing ribozyme platform technology. This is the second Fast Track designation for RZ-001, following its designation for glioblastoma in November 2023. Rznomics has also received FDA approval for an Expanded Access Program...

Rznomics2025-02-17